Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.
The influence of postnatal iron overload upon implications of the functional and interactive role of dopaminergic and noradrenergic pathways that contribute to the expressions of movement disorder and psychotic behaviours in mice was studied in a series of experiments. (1) Postnatal iron overload at doses of 7.5 mg/kg (administered on Days 10-12 post partum) and above, invariably induced a behavioural syndrome consisting of an initial (1st 20-40 min of a 60-min test session) hypoactivity followed by a later (final 20 min of a 60-min test session) hyperactivity, when the mice were tested at adult ages (age 60 days or more). (2) Following postnatal iron overload, subchronic treatment with the neuroleptic compounds, clozapine and haloperidol, dose-dependently reversed the initial hypoactivity and later hyperactivity induced by the metal. Furthermore, DA D(2) receptor supersensitivity (as assessed using the apomorphine-induced behaviour test) was directly and positively correlated with iron concentrations in the basal ganglia. (3) Brain noradrenaline (NA) denervation, using the selective NA neurotoxin, DSP4, prior to administration of the selective DA neurotoxin, MPTP, exacerbated both the functional (hypokinesia) and neurochemical (DA depletion) effects of the latter neurotoxin. Treatment with L-Dopa restored motor activity only in the animals that had not undergone NA denervation. These findings suggest an essential neonatal iron overload, termed "the Youdim factor", directing a DA-NA interactive component in co-morbid disorders of nigrostriatal-limbic brain regions.
Archer
Trevor
T
Department of Neuroscience & Psychiatry, Ulleråker, University of Uppsala, Uppsala, 750 17, Sweden. Trevor.Archer@psy.gu.se
Fredriksson
Anders
A
D000818:Animals; D000831:Animals, Newborn; D014150:Antipsychotic Agents / Q000494:pharmacology; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology; D002395:Catecholamines / Q000502:physiology*; D003024:Clozapine / Q000494:pharmacology; D003714:Denervation; D004298:Dopamine / Q000502:physiology; D015259:Dopamine Agents / Q000494:pharmacology; D005260:Female; D006220:Haloperidol / Q000494:pharmacology; D007501:Iron / Q000378:metabolism; D019190:Iron Overload / Q000503:physiopathology* / Q000523:psychology*; D007980:Levodopa / Q000494:pharmacology; D020267:MPTP Poisoning / Q000378:metabolism / Q000523:psychology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000502:physiology; D009069:Movement Disorders / Q000503:physiopathology; D009638:Norepinephrine / Q000502:physiology; D011247:Pregnancy; D011618:Psychotic Disorders / Q000503:physiopathology; D015398:Signal Transduction / Q000502:physiology; D015430:Weight Gain / Q000187:drug effects
D014150:Antipsychotic Agents; D002395:Catecholamines; D015259:Dopamine Agents; D007980:Levodopa; D007501:Iron; D003024:Clozapine; D006220:Haloperidol; D004298:Dopamine; D009638:Norepinephrine
Eur J Pharmacol. 1991 Sep 17;202(2):177-83
1687031
J Neural Transm Suppl. 1995;46:157-64
8821051
Isr J Med Sci. 1993 Sep;29(9):587-92
7901181
Radiology. 1986 May;159(2):493-8
3961182
J Comp Physiol Psychol. 1982 Jun;96(3):491-516
7096685
Eur J Pharmacol. 1981 Jun 19;72(2-3):173-88
6265244
Eur J Pharmacol. 1993 Jun 4;236(3):487-9
7689466
Mol Chem Neuropathol. 1989 Jun;10(3):171-83
2669769
Lancet. 1987 Nov 21;2(8569):1219-20
2890848
Am J Clin Nutr. 1989 Sep;50(3 Suppl):618-25; discussion 625-9
2570524
Pharmacol Toxicol. 1990 Oct;67(4):295-301
2077520
Neurotox Res. 2003;5(1-2):77-94
14628858
Neurotox Res. 2000 Apr;1(4):249-59
12835093
J Neural Transm (Vienna). 2006 Feb;113(2):137-50
16082515
Psychopharmacology (Berl). 1983;81(1):1-5
6415724
Ann N Y Acad Sci. 2004 Mar;1012:306-25
15105275
Behav Brain Res. 2003 Feb 17;139(1-2):31-46
12642174
Neuroscience. 1983 Aug;9(4):889-98
6312376
J Pharmacol Exp Ther. 1981 Dec;219(3):695-700
7197719
Brain Res Brain Res Rev. 2004 Apr;45(1):38-78
15063099
J Neural Transm (Vienna). 2004 Oct;111(10-11):1455-71
15480846
Life Sci. 1981 Sep 28;29(13):1341-6
7197320
Amino Acids. 2002;23(1-3):111-32
12373526
Psychopharmacology (Berl). 1990;100(4):504-8
2320711
Ann Clin Psychiatry. 2003 Mar;15(1):33-48
12839431
Behav Neural Biol. 1985 May;43(3):238-49
3842248
Neurotox Res. 2000 Apr;1(4):235-47
12835092
Eur J Pharmacol. 1976 Oct;39(2):275-82
185062
Nutrition. 2000 Jul-Aug;16(7-8):504-8
10906537
Behav Brain Res. 2001 Sep 28;124(1):77-85
11423168
Exp Neurol. 1991 Oct;114(1):73-81
1915737
Neuroscience. 1982;7(11):2895-907
7155358
Science. 1969 Oct 31;166(3905):635-7
5823302
J Pharm Pharmacol. 1976 May;28(5):458-9
6763
Brain Res Dev Brain Res. 1990 Aug 1;55(1):35-42
2208639
Med Biol. 1981 Jun;59(3):161-9
6796787
Eur J Pharmacol. 1970;11(3):315-20
5477308
J Neurochem. 2005 Oct;95(1):68-78
16181413
Neuropharmacology. 1974 Nov;13(10-11):927-40
4474641
Toxicol Appl Pharmacol. 1999 Aug 15;159(1):25-30
10448122
J Neurochem. 1991 Nov;57(5):1584-92
1919575
J Neurochem. 1990 Apr;54(4):1136-41
1968955
Br J Pharmacol. 1976 Dec;58(4):521-7
1000130
Brain Res. 1990 Jun 4;518(1-2):31-9
2390723
Psychopharmacology (Berl). 1994 Apr;114(3):383-91
7855196
Eur J Pharmacol. 1993 Nov 2;249(1):37-41
7506666
Bioorg Med Chem. 2005 Feb 1;13(3):773-83
15653345
Neurosci Lett. 1991 Feb 25;123(2):244-7
2027538
J Neural Transm Gen Sect. 1992;87(3):225-30
1533773
Eur J Pharmacol. 1985 Jul 17;113(2):159-65
2864265
J Pharmacol Exp Ther. 1975 Apr;193(1):88-94
166158
Mov Disord. 1993;8(1):1-12
8419792
Psychopharmacology (Berl). 1982;76(4):303-9
6812102
Pharmacol Biochem Behav. 1983 Jul;19(1):121-30
6684774
Brain Res Dev Brain Res. 2000 Jan 3;119(1):65-74
10648873
J Neurol Sci. 1995 Dec;134 Suppl:69-78
8847547
Life Sci. 1985 Jan 21;36(3):201-6
2857048
J Neural Transm (Vienna). 2003 Feb;110(2):183-200
12589577
J Pharmacol Exp Ther. 1997 Oct;283(1):100-7
9336313
Eur Neurol. 1991;31 Suppl 1:34-40
1649757
Pharmacol Biochem Behav. 1986 Jul;25(1):141-4
3018790
Brain Res. 1990 Oct 1;528(2):181-8
2271921
Eur J Pharmacol. 1986 Oct 7;129(3):339-45
3490988
Naunyn Schmiedebergs Arch Pharmacol. 1977 Jan;296(2):183-5
834317
Eur J Pharmacol. 1983 Apr 22;89(1-2):27-33
6861888
Bibl Anat. 1982;(23 ):76-92
6291505
J Neurochem. 1989 Feb;52(2):515-20
2911028
Eur J Pharmacol. 1984 Aug 17;103(3-4):197-204
6149136
Eur J Pharmacol. 1977 Dec 15;46(4):363-9
590344
Parkinsonism Relat Disord. 2001 Apr;7(2):97-105
11248590
J Neurochem. 1958 Oct;3(1):41-51
13611557
Neurotox Res. 2003;5(1-2):53-76
14628856
Arch Neurol. 1991 Dec;48(12):1285-93
1845035
Psychopharmacology (Berl). 1986;88(2):141-6
3081924
J Neural Transm Park Dis Dement Sect. 1994;7(2):123-32
7710664
Neurotox Res. 2001 Oct;3(5):411-32
14715456
Neurotox Res. 2002 Aug-Sep;4(5-6):503-522
12754163
Neurol Clin. 1992 May;10(2):405-20
1584182
Eur J Pharmacol. 1987 May 7;137(1):107-16
2886347
J Neurochem. 1966 Aug;13(8):655-69
5950056
J Pharmacol Exp Ther. 1989 Oct;251(1):238-46
2571717
Eur J Pharmacol. 1986 Jan 29;120(3):295-307
3081358
Neurotox Res. 2006 Oct;10(2):123-9
17062374
Br Med Bull. 1993 Jul;49(3):577-87
8221024
J Med Chem. 1995 Jan 6;38(1):150-60
7530773
J Neurochem. 1994 Sep;63(3):793-807
7519659
J Neural Transm (Vienna). 1999;106(3-4):283-300
10392537
Life Sci. 1985 Oct 14;37(15):1419-23
4046742
J Pharmacol Exp Ther. 1991 Jul 1;258(1):58-65
1830099
J Neural Transm (Vienna). 2006 Sep;113(9):1119-29
16362627
Brain. 1991 Aug;114 ( Pt 4):1953-75
1832073
Br J Pharmacol. 1984 May;82(1):249-57
6733355
J Clin Psychiatry. 1998;59 Suppl 3:38-43
9541337
Nat Rev Neurosci. 2004 Nov;5(11):863-73
15496864
Neurodegeneration. 1996 Sep;5(3):241-9
8910902
Ann N Y Acad Sci. 1999;890:7-25
10668410